Mecics, a company specializing in respiratory therapy devices, is hitting the upper price limit.


At 10:35 AM on the 24th, Mecics is trading at 4,535 KRW, up 26.32% compared to the previous day.


This is interpreted as being influenced by the resurgence of COVID-19 in China. On the 22nd, local Chinese media reported that Chinese epidemic prevention experts predicted the peak of the second COVID-19 wave would occur by the end of next month.



Mecics is a specialized company in ventilators and respiratory therapy devices. As of the end of January, it supplied 700 units of the respiratory therapy drug HFT500 to China.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing